Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

New concepts regarding events that lead to end-stage heart disease

  • 17 Accesses

  • 4 Citations

Summary

Cardiac dysfunction is a progressive process that eventuates in end-stage heart failure. This progression involves dilatation and hypertrophy of the left ventricle, characterized as left ventricular remodeling. This remodeling results in a falling left ventricular ejection fraction, worsening heart failure, and increased risk of lethal ventricular arrhythmias. Increased aortic impedance due to vasoconstriction, neurohormonal stimulation, and bioenergetic abnormalities all may contribute to the remodeling process. Therapeutic efforts aimed at halting this progressive process, especially if initiated early in the course of the disease, are most likely to exert a favorable effect.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical complications.Circulation 1990;81:1161–1172.

  2. 2.

    Anversa P, Ricci R, Olivette G. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: A review.J Am Coll Cardiol 1986;7:1140.

  3. 3.

    Cohn JN, Johnson GR, Shabetai R, et al. for the V-HeFT VA Cooperative Studies Group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure.Circulation 1993;87:V15-VI16.

  4. 4.

    White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume is the major determinant of survival after recovery from myocardial infarction.Circulation 1987;76:44–51.

  5. 5.

    McDonald KM, Mock J, D'Aloia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium following discrete transmural myocardial necrosis.Circulation 1995, in press.

  6. 6.

    Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT).N Engl J Med 1986;314:1547–1552.

  7. 7.

    Cohn JN. Heart failure. In: Willerson JT, Cohn JN, eds.Cardiovascular Medicine. New York: Churchill Livingstone, 1995:947–979.

  8. 8.

    Linzbach AJ. Heart failure from the point of view of quantitative anatomy.Am J Cardiol 1960;5:370–382.

  9. 9.

    Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle.J Clin Invest 1975;56:56–64.

  10. 10.

    Komuro I, Kaida T, Shibazaki Y, et al. Stretching cardiac myocytes stimulates protooncogene expression.J Biol Chem 1990;265:3595–3598.

  11. 11.

    Simpson P. Norepinephrine stimulated hypertrophy of cultured rat myocardial cells is an α-1 adrenergic response.J Clin Invest 1983;72:732–738.

  12. 12.

    McDonald KM, Francis GS, Carlyle PF, et al. Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog.J Am Coll Cardiol 1992;19:460–67.

  13. 13.

    McDonald KM, Francis GS, Matthews JH, Hunter D, Cohn JN. Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog.J Am Coll Cardiol 1993;21:514–522.

  14. 14.

    Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure.J Clin Invest 1992;90:1523–1529.

  15. 15.

    McDonald KM, D'Aloia A, Parrish T, Mock J, Cohn JN. The impact of converting enzyme inhibition on global and regional systolic function in a canine model of ventricular remodeling.Circulation 1994;90:1262.

  16. 16.

    Weber KT. Cardiac interstitium in health and disease: The fibrillar collagen network.J Am Coll Cardiol 1989;13–17:1637–1652.

  17. 17.

    Sonnenblick EH, Ross J Jr, Braunwald E. Oxygen consumption of the heart. New concepts of its multifactorial determination.Am J. Cardiol 1968;22:328.

  18. 18.

    Gaaschl WH, Alexander JK, Cole JS, Quinones MA. Dynamic determinants of left ventricular diastolic pressure-volume relations in man.Circulation 1975;51:317–323.

  19. 19.

    Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitum. Fibrosis and renin-angiotensin-aldosterone system.Circulation 1991;83:1849–1865.

  20. 20.

    Weber KT, Brilla CH, Cleland JGF, et al. Cardioreparation and the concept of modulating cardiovascular structure and function.Blood Pressure 1993;2:6–21.

  21. 21.

    Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT II.Circulation 1993;87:VI40-VI48.

  22. 22.

    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med 1991;325:293–302.

  23. 23.

    Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.N Engl J Med 1991;325:303–310.

  24. 24.

    Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure.Circulation 1992;85:504–509.

  25. 25.

    Levine B, Kalman J, Mayer L, Fellet HM, Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure.N Engl J Med 1990;323:236–241.

  26. 26.

    Salisbury PF, Cross CE, Rieban PA. Acute ischemia of inner layers of ventricular wall.Am Heart J 1963;66:650.

  27. 27.

    McDonald KM, Yoshiyama M, Francis GS, Ugurbil K, Cohn JN, Zhang J. Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction.J Am Coll Cardiol 1994;23:786–793.

  28. 28.

    Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson P, Cohn JN, for the V-HeFT VA Cooperative Studies Group. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure.Circulation 1993;87:VI49-VI55.

  29. 29.

    Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G, for the V-HeFT VA Cooperative Studies Group. Mechanism of death in heart failure: The Vasodilator-Heart Failure Trials.Circulation 1993;87:VI24-VI31.

  30. 30.

    The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.N Engl J Med 1989;321:406–412.

  31. 31.

    Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure.Lancet 1994;344:493–498.

  32. 32.

    Singh SN, Fletcher RD, Fisher SG, et al. Results of the congestive heart failure survival trial of antiarrhythmic therapy (abstr).Circulation 1994;90:I546.

Download references

Author information

Correspondence to Jay N. Cohn M.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cohn, J.N. New concepts regarding events that lead to end-stage heart disease. Cardiovasc Drug Ther 9, 489–492 (1995). https://doi.org/10.1007/BF00877859

Download citation

Key Words

  • ventricular remodeling
  • neurohormonal stimulation
  • bioenergetics